Lexeo Therapeutics Announces FDA Support for Accelerated Approval Pathway, Positive Interim Data for Gene Therapy LX2006

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is one of the best young stocks with huge upside potential. On October 7, Lexeo Therapeutics announced progress regarding its gene therapy candidate, LX2006, for Friedreich ataxia/FA cardiomyopathy. The company shared positive updates from discussions with the US FDA on an Accelerated Approval pathway, along with encouraging new interim clinical data from ongoing Phase I/II studies. Lexeo’s leadership believes this combination of regulatory support and compelling data ...